CRNX has completed a remarkable repositioning since the Vertex Pharmaceuticals acquisition announcement: the short book that once represented nearly 13% of the free float has been cut to a fraction of its former size, and the stock is now trading squarely on deal mechanics at $84.36 — effectively pinned to the $85 per share cash bid.
The short-side unwind is the headline data point this week. Short interest has fallen another 38% over the past seven days to just 4.6% of the free float, representing roughly 4.35 million shares — down from 6.9 million a week ago and from a peak of more than 13 million in early July. That is a collapse of two-thirds in six weeks. Borrow conditions reinforce the picture: availability has surged to 2,397% — meaning there are now more than twenty-three times as many shares available to lend as there are shares actually borrowed — while the cost to borrow has dropped to 0.32%, down from over 0.5% in late June. Shorts are not just stepping back; the lending market is increasingly empty of meaningful short activity. The ORTEX short score has moved in lockstep, falling to 34.4 from above 40 a week ago, reflecting the unwinding pressure across every dimension of the short setup.
Options positioning has moved modestly more defensive, though not dramatically so. The put/call ratio sits at 0.56, above its 20-day average of 0.48 by about 1.25 standard deviations. That is elevated relative to recent norms but nowhere near the 0.99 reading seen in early July when the deal was still being priced. The most plausible reading is that some holders are buying puts as deal-close insurance rather than expressing a fundamental bear view — a rational hedge when the entire thesis rests on regulatory and shareholder approval.
The analyst community has effectively conceded the deal. In early July, a wave of downgrades swept through the coverage universe — UBS, TD Cowen, Evercore ISI, Jefferies, Cantor Fitzgerald, and others all moved to Hold or equivalent, many simultaneously raising price targets to $85 to reflect the cash bid. The result is a consensus rating of Hold with a mean price target of $85.50, essentially flat to the deal price. With only one Buy remaining against thirteen Hold ratings, the Street has pivoted from debating CRNX's pipeline to debating deal completion risk. The bull case at this point rests entirely on Vertex's $10 billion all-cash offer closing as structured. The bear case is the mirror image: the stock trades at a thin spread to the deal price, meaning any deal disruption would send the shares materially lower — and insiders were selling in the $37–$40 range as recently as April, well before the stock repriced into the $80s.
Institutional holders have been adding through the transition. BlackRock increased its position to 9.2% of shares as recently as July 31. T. Rowe Price added over two million shares through June 30, lifting its stake to 6.9%. Farallon Capital, typically an active arbitrage player, holds 8.5% — a detail that speaks more to merger-arb positioning than to long-term fundamental conviction.
The next formal milestone is the Q3 earnings report, currently scheduled for November 9 — well after the deal is expected to close. With the prior earnings release on August 4 producing a 29% one-day move and a 72% five-day move as the market absorbed the acquisition news, the event-driven phase is effectively behind the stock. What to watch from here is the spread between the current price and the $85 deal price, any regulatory filings or shareholder vote announcements that clarify the close timeline, and whether the residual short position — still 4.6% of float — continues to compress toward zero or stabilises as a base of deal-risk hedgers.
See the live data behind this article on ORTEX.
Open CRNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
